GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

Informazioni relative al progetto

GUIDE.MRD

ID dell’accordo di sovvenzione: 101112066

DOI

10.3030/101112066

Data della firma CE 17 Maggio 2023

Data di avvio 1 Maggio 2023

Data di completamento 30 Aprile 2028

Finanziato da

• Health

Costo totale

€ 34 948 425,41

Contributo UE

€ 17 660 955,00

Coordinato da

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (4)

Updated Data Management Plan (DMP)

The DMP will be updated based on the progress of WP2 and WP3 and associated deliverables

Healthcare pathway map

Visualization of existing and the (ideal) pathway according to a common framework

Stakeholder/system map

A map representing connectivity, fragmentation and factors in the system that may influence adoption of new technologies and solutions.

Dissemination and exploitation plan, including IPR protection management, communication activities

An initial dissemination, communication and exploitation plan will be created when the project begins and updated yearly. The plan will be organized according to the specific conditions on Availability, Accessibility and Affordability (‘3A’).

Websites, patent fillings, videos etc. (1)

Development of project website and project visual identity

The GUIDE.MRD website will be accessible on the internet with internal access that is password protected

Pubblicazioni

Conference proceedings (1)

Creation of the ideal health care pathway for integrating ctDNA testing into clinical practice through multi-stakeholder engagement.

Autori: Lidewij Vat, Brian Goodman, Eleonora Barile, Estevan Kiernan, Bianca Cucoş, Ana Martins, Mohan Bolisetty, Cathy Elks, Ryan Demers, Muriel De Vos, Riccardo Bertini, Trixia Camacho, Daniel J. Smit, Lui
Pubblicato in: Journal of Clinical Oncology, Numero 43, 2025, ISSN 0732-183X
Editore: American Society of Clinical Oncology (ASCO)
DOI: 10.1200/JCO.2025.43.16_SUPPL.E23032

Peer reviewed articles (2)

Outlining the statistical analysis of longitudinal ctDNA assays to determine minimal residual disease in patients with pancreatic ductal adenocarcinoma: the GUIDE.MRD project

Autori: Brune De Dreuille, Evangelina López De Maturana, Claus Lindbjerg Andersen, Ed Schuuring, Ellen Heitzer, Lidewij Vat, Mark Rogers, Riccardo Bertini, Estevan Kiernan, Ephrem Chin, J. Carl Barrett, Josh
Pubblicato in: Pancreatology, Numero 24, 2024, ISSN 1424-3903
Editore: Elsevier BV
DOI: 10.1016/J.PAN.2024.05.293

237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to i

Autori: K. Pantel, C. Lindbjerg Andersen, E. Schuuring, N. Malats, E. Heitzer, L. Vat, E. Kiernan, E. Chin, J.C. Barrett, J.R. Kapp, M. Thomas, M. Gerling, M. Reck, M. Löhr, P. Hofman, J.T.J.N. Hiltermann, C
Pubblicato in: Annals of Oncology, Numero 34, 2025, ISSN 0923-7534
Editore: Elsevier BV
DOI: 10.1016/J.ANNONC.2023.09.2960EXTERNALLINK